GC Biopharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
GC Biopharma makes medicines including blood-derived therapies, vaccines, prescription drugs, and over-the-counter products for human health.
It supplies these products to general hospitals, clinics, pharmaceutical wholesalers, pharmacies, and the Red Cross. Listed on KOSPI, Korea's main stock exchange, the company's product portfolio is anchored by blood-derived therapies and vaccines, which lead its overall medicine lineup.
Summary is AI-generated and may contain errors · figures from DART filings
GC Biopharma in five facts
What does GC Biopharma do?
GC Biopharma makes medicines including blood-derived therapies, vaccines, prescription drugs, and over-the-counter products for human health.
Where is GC Biopharma listed and in which sector?
GC Biopharma (Korean name: 녹십자) trades under KRX code 006280 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is GC Biopharma?
Its market capitalisation was US$1.2B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were GC Biopharma's latest annual revenue and operating profit?
For fiscal year 2025, GC Biopharma reported revenue of US$1.5B, operating profit of US$52.2M and a net loss of US$22.4M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 18.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (consolidated) (preliminary) (fair disclosure)
GC Biopharma filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$296M (−15.8% year on year), operating profit of US$1.2M (−93.8% year on year) and net income of US$774K (−96.6% year on year).
Earnings · Jul 31 - Operating results (consolidated) (preliminary) (fair disclosure)
GC Biopharma filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$299M (+13.5% year on year), operating profit of US$8.04M (+46.3% year on year) and net income of US$13.8M (−9.9% year on year).
Earnings · May 8 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
GC Biopharma updated its previously filed consolidated results for FY2025: revenue of US$1.34B (+18.5% year on year), operating profit of US$46.6M (+115.4% year on year) and a net loss of US$20M.
Earnings · Mar 9 · 2 versions - Cash/in-kind dividend decision
GC Biopharma declared a cash dividend of US$1.03 per share.
Dividend · Feb 11